ethylmaleimide has been researched along with Glycogen Storage Disease Type I in 1 studies
Ethylmaleimide: A sulfhydryl reagent that is widely used in experimental biochemical studies.
Glycogen Storage Disease Type I: An autosomal recessive disease in which gene expression of glucose-6-phosphatase is absent, resulting in hypoglycemia due to lack of glucose production. Accumulation of glycogen in liver and kidney leads to organomegaly, particularly massive hepatomegaly. Increased concentrations of lactic acid and hyperlipidemia appear in the plasma. Clinical gout often appears in early childhood.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Leuzzi, R | 1 |
| Bánhegyi, G | 1 |
| Kardon, T | 1 |
| Marcolongo, P | 1 |
| Capecchi, PL | 1 |
| Burger, HJ | 1 |
| Benedetti, A | 1 |
| Fulceri, R | 1 |
1 other study available for ethylmaleimide and Glycogen Storage Disease Type I
| Article | Year |
|---|---|
Inhibition of microsomal glucose-6-phosphate transport in human neutrophils results in apoptosis: a potential explanation for neutrophil dysfunction in glycogen storage disease type 1b.
Topics: 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; Antioxidants; Apoptosis; Biological Transport; Cel | 2003 |